Summary of Clinical Use

Landogrozumab has reached Phase 2 clinical trial as a potential therapy for conditions characterised by muscle weakness or muscle wasting, including cachexia as an effect of advanced pancreatic cancer and muscular atrophy requiring total hip replacement.

Mechanism Of Action and Pharmacodynamic Effects

Landogrozumab binds to myostatin, a type II activin receptor ACVR2B agonist, and neutralises ligand-induced receptor activation. This action blocks myostatin-induced SMAD pathway signalling, which is hypothesised to improve the formation of skeletal muscle [1,3-4]. This is in contrast to bimagrumab which targets the same pathway at the receptor level rather than at the ligand level.